Front. Oncol.Frontiers in OncologyFront. Oncol.2234-943XFrontiers Media S.A.10.3389/fonc.2020.00684OncologyCorrectionCorrigendum: Fingolimod Augments Monomethylfumarate Killing of GBM CellsDentPaul1*BoothLaurence1*RobertsJane L.1PoklepovicAndrew2HancockJohn F.31Departments of Biochemistry and Molecular Biology, Virginia Commonwealth University, Richmond, VA, United States2Departments of Medicine, Virginia Commonwealth University, Richmond, VA, United States3Department of Integrative Biology and Pharmacology, University of Texas Health Science Center, Houston, TX, United States
Edited and reviewed by: Liam Chen, Johns Hopkins University, United States
*Correspondence: Paul Dent paul.dent@vcuhealth.orgLaurence Booth laurence.booth@vcuhealth.org
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Oncology
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Fingolimod Augments Monomethylfumarate Killing of GBM Cells by Dent, P., Booth, L., Roberts, J. L., Poklepovic, A., and Hancock, J. F. (2020). Front. Oncol. 10:22. doi: 10.3389/fonc.2020.00022fingolimoddimethyl fumarateGilenyaTecfideraRASglioblastomamicroglia
In the original article, there was a mistake in Figure 7C as published. By error, the image for FAS-L treated with MMF was included twice; once correctly and once as FAS-L treated with vehicle control. The corrected Figure 7C for FAS-L assessments appears below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.